Aeterna Zentaris Inc. announced the appointment of Klaus Paulini as President and Chief Executive Officer of the company, effective October 4, 2019, replacing Michael Ward. Dr. Paulini will also serve as a Director of the company. Dr. Paulini will continue to be based in Frankfurt, Germany, and his appointment as President and Chief Executive Officer aligns with the Company's refocus on its operations in Germany.

The Company's registered office will remain in Toronto, Ontario, Canada. Dr. Paulini began his career in the pharmaceutical industry at ASTA Medica AG in 1997. He had an active role in the spinoff and formation of Aeterna Zentaris GmbH from ASTA Medica.

Dr. Paulini has managed many of the company's clinical development projects including research and development of Macrilen (macimorelin).